[{"from": "human", "value": "Could you provide a description of this molecule? [C][O][C][=C][Branch2][Ring2][=Branch1][C][=C][C][=C][N][C][C][N][Ring1][Branch1][C][=Branch1][P][=N][C][=Branch1][C][=O][C][=C][N][=C][Branch1][Branch1][N][=C][Ring1][=Branch1][N][N][=C][Ring2][Ring1][Ring1][Ring2][Ring1][#Branch1][O][C][C][C][N][C][C][O][C][C][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is an imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of morpholines, an aromatic ether, a diether, a tertiary amino compound, a secondary carboxamide, a pyrimidinecarboxamide, an aminopyrimidine and an imidazoquinazoline."}]